Skip to main content

Table 3 Attitudes regarding access to care and treatment recommendations

From: Oncologists’ and family physicians’ views on value for money of cancer and congestive heart failure care

 

% stating strongly or somewhat agree

P value

Oncologists

Family physicians

Whether a cancer drug is included in the National List of Health Services influences my decision regarding which cancer treatment to recommend to my patients

77%

54%

0.005

Whether an intervention for congestive heart failure is included in the National List of Health Services influences my decision regarding which treatment to recommend to my patients

 

65%

 

Whether a cancer drug is included in the National List of Health Services highly influences my patients’ access to treatment

92%

84%

NS

Whether a treatment for congestive heart failure is included in the National List of Health Services highly influences my patients’ access to treatment

 

86%

 

Every patient in Israel should have access to effective cancer treatments regardless of their cost

65%

55%

NS

Every patient in Israel should have access to effective treatments for congestive heart failure regardless of their cost

73%

59%

NS

Every effective cancer drug that is not included in the National List of Health Services should be included in the supplementary insurance offered by health plans

65%

76%

NS

Every effective treatment for congestive heart failure that is not included in the National List of Health Services should be included in the supplementary insurance offered by health plans

65%

78%

NS

Every effective cancer drug that is not included in the National List of Health Services should be included in commercial health insurance plans offered by private health insurance companies

75%

72%

NS

Co-payment on cancer drugs is needed even if the drugs are included in the National List of Health Services

10%

10%

NS

More research on comparative analysis of cancer drugs is needed

83%

85%

NS

Data on the cost-effectiveness of new cancer drugs may have an impact on which treatment protocol to recommend to my patients

52%

64%

NS

The notion that my patients will have to pay for a cancer drug “out of pocket” will influence my decision regarding which treatment protocol to recommend to my patients

79%

56%

NS

How often do you discuss the costs of cancer drugs with your patients?

   

 Always

6%

1%

0.007

 Frequently

17%

14%

 

 Occasionally

50%

36%

 

 Rarely

27%

34%

 

 Never

0%

16%

 

How often do you discuss the costs of treatments for congestive heart failure with your patients?

   

 Always

 

2%

 

 Frequently

 

16%

 

 Occasionally

 

30%

 

 Rarely

 

33%

 

 Never

 

19%